Cargando…
c-Src Binds to the Cancer Drug Ruxolitinib with an Active Conformation
The cancer drug Ruxolitinib is a potent janus kinase inhibitor approved for the treatment of the myeloproliferative neoplasms. In addition, Ruxolitinib has weak inhibitory activity against a panel of other kinases, including Src kinase. There is no structural information of Ruxolitinib binding to an...
Autores principales: | Duan, Yankun, Chen, Lin, Chen, Yongheng, Fan, Xue-gong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157781/ https://www.ncbi.nlm.nih.gov/pubmed/25197973 http://dx.doi.org/10.1371/journal.pone.0106225 |
Ejemplares similares
-
Conformational Selection and Induced Fit Mechanisms in the Binding of an Anticancer Drug to the c-Src Kinase
por: Morando, Maria Agnese, et al.
Publicado: (2016) -
Tyrosine 416 Is Phosphorylated in the Closed, Repressed Conformation of c-Src
por: Irtegun, Sevgi, et al.
Publicado: (2013) -
Src Kinase Conformational Activation: Thermodynamics, Pathways, and Mechanisms
por: Yang, Sichun, et al.
Publicado: (2008) -
A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
por: Temps, Carolin, et al.
Publicado: (2021) -
Computational
Study of the “DFG-Flip”
Conformational Transition
in c-Abl and c-Src Tyrosine Kinases
por: Meng, Yilin, et al.
Publicado: (2014)